This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 12, 2021
Baxter Invests in its German Sterile Fill/Finish Manufacturing Facility
Author(s)BioPharm International Editors
Baxter will invest $100 million in new lyophilization equipment and an additional aseptic syringe filling line at its Halle/Westfalen (Germany) location.
Advertisement
Baxter International announced its plans to invest approximately $100 million in expansions to its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany on Nov. 11, 2021. The Halle/Westfalen facility is operated by Baxter BioPharma Solutions (BPS), a division of Baxter specializing in contract development and manufacturing of drug products for parenteral pharmaceuticals. Construction on the new facility is expected to begin in 2022 and complete in 2024.
The planned additions include new lyophilization equipment and a new aseptic syringe filling line. According to a company press release, the new lyophilization equipment is intended to further increase product stability and shelf life, while the additional aseptic line will help the company meet growing demand for pre-filled syringes in Europe and the United States.
“Baxter’s manufacturing site in Halle/Westfalen is one of the most advanced facilities in our global network and has seen significant growth over the last several years,” said Marie Keeley, general manager, Baxter BioPharma Solutions, in the press release. “By making this investment, we are building on recent expansions to help ensure this facility can serve our partners at the highest level now and well into the future.”
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5